Metynor (Methylphenidate Hydrochloride)

Methylphenidate hydrochloride blocks the reuptake of the neurotransmitters dopamine and norepinephrine, raising their levels in the synaptic cleft. The increased catecholamine activity enhances signaling in brain pathways that control attention, impulse control and wakefulness, which helps alleviate the core symptoms of ADHD and narcolepsy.

The appropriate dose of Metynor is individualized by a qualified prescriber based on the patient’s age, weight, clinical response and tolerability. Dosage adjustments are made during treatment to achieve optimal benefit while minimizing adverse effects.

Safety data for methylphenidate hydrochloride in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss them with the patient. Use is generally reserved for situations where the therapeutic advantage justifies potential fetal or infant exposure.

To request Metynor, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Metynor (methylphenidate) is a stimulant that directly increases dopamine and norepinephrine levels, similar to other methylphenidate products and amphetamine‑based agents. Compared with non‑stimulant options, it typically offers a faster onset of action but may carry a higher risk of cardiovascular and psychiatric side effects, requiring careful monitoring.

Metynor should be stored at ambient temperature, below 25 °C (77 °F). Keep the product in its original packaging, protect it from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Metynor is taken orally, usually as a tablet or capsule, and should be swallowed whole with water. It is typically taken once or twice daily, with or without food, according to the prescribing clinician’s instructions.

Serious risks include cardiovascular events such as hypertension, arrhythmia, or myocardial infarction; psychiatric effects like psychosis, severe anxiety, or suicidal thoughts; and rare but severe allergic reactions. Patients should be monitored regularly for these adverse outcomes, especially during treatment initiation and dose changes.

Metynor is contraindicated in individuals with known hypersensitivity to methylphenidate or any formulation component, those currently taking monoamine oxidase inhibitors, and patients with severe cardiovascular disorders, uncontrolled hypertension, or a history of serious psychiatric conditions unless closely supervised by a specialist.